UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042578
Receipt number R000048546
Scientific Title Confirmatory study of the effect of ingestion of food containing seaweed extract on the intestinal environment
Date of disclosure of the study information 2021/01/08
Last modified on 2021/08/18 11:10:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Confirmatory study of the effect of ingestion of food containing seaweed extract on the intestinal environment

Acronym

Confirmatory study of the effect of ingestion of food containing seaweed extract on the intestinal environment

Scientific Title

Confirmatory study of the effect of ingestion of food containing seaweed extract on the intestinal environment

Scientific Title:Acronym

Confirmatory study of the effect of ingestion of food containing seaweed extract on the intestinal environment

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to investigate the effect on the intestinal environment of healthy Japanese men and women aged 20 to 60 years by continuous intake of seaweed polyphenols for 4 weeks.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Stool test (intestinal flora)

Key secondary outcomes

(Secondary outcomes)
Defecation survey form (defecation frequency, feces, stool odor, stool color, stool volume, discomfort after defecation), stool tests(decay product content in feces, ammonia content in feces, stool odor stool short-chain fatty acid)
(Safety evaluation)
Vital signs, physical measurement, blood biochemistry, hematology, urinalysis, adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

4-weeks intake of the test food

Interventions/Control_2

4-weeks intake of the placebo food

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Healthy Japanese men and women aged between 20 and 60 at the time of obtaining written informed consent
2.Subject with constipation tendency (4 bowel movements / week or less, excluding severe constipation)
3.Subject who can record the questionnaire on the web during the test period
4.Subject who can come to the venue on the designated inspection date and undergo inspection
5.Subject who has received sufficient explanation of the purpose and content of the research, have the ability to consent, voluntarily volunteered to participate in the examination after understanding it well, and agreed to participate in the examination in writing

Key exclusion criteria

1.Subject with a history of comorbidities in the digestive organs (excluding a history of cecum)
2.Subject who is taking medication or under medical treatment
3.Subject who is under exercise therapy or dietetic therapy
4.Subject who may develop allergies due to the test foods and who may cause serious allergic symptoms to other foods and medicines
5.Subject with current or history of drug dependence or alcohol dependence
6.Heavy drinkers
7.Subject who is out of the hospital due to mental disorders (depression, etc.) or sleep disorders, or who have a history of mental illness in the past
8.Subject with irregular life rhythms due to night shifts or shift work
9.Subject with extremely irregular lifestyle habits such as eating and sleeping
10.Subject who has an extremely unbalanced diet
11.Subject who has difficulty in taking the full amount of the prescribed diet
12.Serious diseases such as brain disease, malignant tumor, immune disease, diabetes, liver disease (hepatitis), renal disease, heart disease, thyroid disease, adrenal disease, and other serious current or past diseases such as metabolic disease those who have
13.Subject who uses health foods, supplements, and medicines that have an intestinal regulating effect
14.Subject who has participated in other clinical trials (research) within 3 months from the date of consent acquisition or who plan to participate in other clinical trials (research) during the trial period
15.Subject who has collected 200 mL of blood or donated more than 400 mL of blood within 3 months from the date of consent acquisition
16.Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating
17.Subject who has a smoking habit
18.Subject who has difficulty observing records on various survey forms
19.Subject who is judged as an inappropriate candidate according to the screening data
20.Subject who is considered as an inappropriate candidate by the doctor in charge

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Email

ochitani@huma-rd.co.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Homepage URL


Email

ochitani@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

RIKEN VITAMIN CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

NISHI-UMEDA Clinic for Asian Medical Collaboration Clinical Research Institutional Review Board

Address

West Umeda Building 3F 3-3-45 Umeda Kita-ku Osaka Japan,530-0001

Tel

06-4797-5660

Email

jimukyoku@amc-clinc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

32

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 11 Month 20 Day

Date of IRB

2020 Year 11 Month 26 Day

Anticipated trial start date

2020 Year 11 Month 27 Day

Last follow-up date

2021 Year 04 Month 21 Day

Date of closure to data entry

2021 Year 05 Month 18 Day

Date trial data considered complete

2021 Year 05 Month 31 Day

Date analysis concluded

2021 Year 06 Month 30 Day


Other

Other related information



Management information

Registered date

2020 Year 11 Month 27 Day

Last modified on

2021 Year 08 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048546


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name